Bovine Herpesvirus-4 Based Vaccine Provides Protective Immunity against Streptococcus suis Disease in a Rabbit Model
dc.contributor.author | Dong, N | |
dc.contributor.author | Nichols, H | |
dc.contributor.author | Sun, Q | |
dc.contributor.author | Chen, X | |
dc.contributor.author | Zheng, J | |
dc.contributor.author | Guan, Z | |
dc.contributor.author | Zhang, H | |
dc.contributor.author | Davison, A | |
dc.contributor.author | Wezel, Y | |
dc.contributor.author | Li, Z | |
dc.contributor.author | Li, B | |
dc.contributor.author | Liu, K | |
dc.contributor.author | Shao, D | |
dc.contributor.author | Qiu, Y | |
dc.contributor.author | Sun, J | |
dc.contributor.author | Li, X | |
dc.contributor.author | Upton, Mathew | |
dc.contributor.author | Ma, Z | |
dc.contributor.author | Jarvis, MA | |
dc.contributor.author | Wei, J | |
dc.date.accessioned | 2023-06-08T21:38:20Z | |
dc.date.available | 2023-06-08T21:38:20Z | |
dc.date.issued | 2023-05-20 | |
dc.identifier.issn | 2076-393X | |
dc.identifier.issn | 2076-393X | |
dc.identifier.other | 1004 | |
dc.identifier.uri | https://pearl.plymouth.ac.uk/handle/10026.1/20965 | |
dc.description.abstract |
Streptococcus suis (S. suis) is a bacterial pathogen of pigs that has a major animal health and economic impact on the pig industry. Bovine herpesvirus-4 (BoHV-4) is a new virus-based vaccine vector that has been used for the immunogenic delivery of antigens from a variety of pathogens. In the present study, two recombinant BoHV-4-based vectors were evaluated for their ability to induce immunity and protection against S. suis in a rabbit model. The GMD protein is a fusion protein consisting of multiple dominant B-cell epitopes ((B-cell dominant epitopes of GAPDH, MRP, and DLDH antigens) (BoHV-4/GMD)) and the second suilysin (SLY) (BoHV-4/SLY) from S. suis serotype 2 (SS2). Both GMD and SLY delivered by the BoHV-4 vectors were recognized by sera from SS2-infected rabbits. The vaccination of rabbits with the BoHV-4 vectors induced antibodies against SS2, as well as against additional S. suis serotypes, SS7 and SS9. However, sera from BoHV-4/GMD-vaccinated animals promoted a significant level of phagocytic activity by pulmonary alveolar macrophages (PAMs) against SS2, SS7, and SS9. In contrast, sera from rabbits immunized with BoHV-4/SLY induced PAM phagocytic activity against only SS2. In addition, BoHV-4 vaccines differed in the associated level of protection against lethal SS2 challenge, which ranged from high (71.4%) to low (12.5%) for BoHV-4/GMD and BoHV-4/SLY, respectively. These data suggest BoHV-4/GMD as a promising vaccine candidate against S. suis disease. | |
dc.format.extent | 1004-1004 | |
dc.format.medium | Electronic | |
dc.language | en | |
dc.publisher | MDPI AG | |
dc.subject | Streptococcus suis | |
dc.subject | BoHV-4 | |
dc.subject | GMD | |
dc.subject | suilysin | |
dc.subject | serotype | |
dc.subject | vector-based vaccine | |
dc.subject | protection | |
dc.title | Bovine Herpesvirus-4 Based Vaccine Provides Protective Immunity against Streptococcus suis Disease in a Rabbit Model | |
dc.type | journal-article | |
dc.type | Journal Article | |
plymouth.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000997128900001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008 | |
plymouth.issue | 5 | |
plymouth.volume | 11 | |
plymouth.publication-status | Published online | |
plymouth.journal | Vaccines | |
dc.identifier.doi | 10.3390/vaccines11051004 | |
plymouth.organisational-group | |Plymouth | |
plymouth.organisational-group | |Plymouth|Research Groups | |
plymouth.organisational-group | |Plymouth|Faculty of Health | |
plymouth.organisational-group | |Plymouth|Research Groups|Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | |Plymouth|Research Groups|Institute of Translational and Stratified Medicine (ITSMED)|CBR | |
plymouth.organisational-group | |Plymouth|REF 2021 Researchers by UoA | |
plymouth.organisational-group | |Plymouth|Users by role | |
plymouth.organisational-group | |Plymouth|Users by role|Academics | |
plymouth.organisational-group | |Plymouth|REF 2021 Researchers by UoA|UoA01 Clinical Medicine | |
plymouth.organisational-group | |Plymouth|Faculty of Health|School of Biomedical Sciences | |
plymouth.organisational-group | |Plymouth|Users by role|Researchers in ResearchFish submission | |
plymouth.organisational-group | |Plymouth|Research Groups|Plymouth Institute of Health and Care Research (PIHR) | |
dc.publisher.place | Switzerland | |
dcterms.dateAccepted | 2023-05-18 | |
dc.date.updated | 2023-06-08T21:38:06Z | |
dc.rights.embargodate | 2023-6-10 | |
dc.identifier.eissn | 2076-393X | |
dc.rights.embargoperiod | forever | |
rioxxterms.versionofrecord | 10.3390/vaccines11051004 |